Table 5.
Multivariate analysis of risk factors associated with OS and PFS.
| Characteristics | OS | PFS | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (>60) | 1.132(0.448-2.862) | 0.793 | 1.239(0.639-2.402) | 0.526 |
| B symptoms | 1.234(0.468-3.258) | 0.671 | 0.588(0.294-1.175) | 0.132 |
| ECOG (>2) | 1.122(0.377-3.340) | 0.837 | 0.996(0.403-2.464) | 0.994 |
| Stage (III/IV) | 5.957(1.505-23.582) | 0.011 | 0.929(0.406-2.125) | 0.862 |
| β2 -MG (>ULN) | 3.692(1.508-9.039) | 0.004 | 1.363(0.720-2.583) | 0.342 |
| bone marrow involvement | 1.907(0.634-5.739) | 0.251 | 1.284(0.582-2.831) | 0.536 |
| ESI>1 | 1.851(0.773-4.432) | 0.167 | 1.154(0.619-2.152) | 0.653 |
| ki-67≥90% | 0.766(0.327-1.793) | 0.539 | 0.574(0.317-1.039) | 0.067 |
| IPI score>2 | 5.753(1.408-23.505) | 0.015 | 1.590(0.758-3.337) | 0.220 |
| High-intensity chemotherapy | 0.262(0.105-0.656) | 0.004 | 0.306(0.153-0.610) | 0.001 |
| HGBLR or HGBL, NOS | 3.147(1.301-7.611) | 0.011 | 3.576(1.853-6.903) | <0.001 |
CI, confidence interval; HR, hazard ratio; OS, Overall survival; PFS, Progression-free survival; ECOG, Eastern Cooperative Oncology Group; ESI, extranodal sites involvement; β2-MG, beta-2 microglobulin level; IPI, international prognostic index; ULN, upper limit of normal.